NASDAQ:BRKR - Bruker Stock Price, Price Target & More

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker announced a quarterly dividend on Tuesday, May 15th. Stockholders of record on Monday, June 4th will be paid a dividend of $0.04 per share on Friday, June 22nd. This represents a $0.16 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Friday, June 1st. View Bruker's Dividend History.

Bruker announced that its board has authorized a share buyback plan on Sunday, June 4th 2017, which allows the company to repurchase $225,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board believes its shares are undervalued.

Bruker (NASDAQ:BRKR) released its quarterly earnings data on Thursday, May, 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.02. The medical research company had revenue of $431.70 million for the quarter, compared to the consensus estimate of $419.25 million. Bruker had a net margin of 4.63% and a return on equity of 27.04%. The company's quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Bruker.

11 analysts have issued 12 month price targets for Bruker's stock. Their predictions range from $24.00 to $42.00. On average, they anticipate Bruker's stock price to reach $32.80 in the next year. View Analyst Ratings for Bruker.

Some companies that are related to Bruker include Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT) and HTG Molecular Diagnostics (HTGM).

Media coverage about BRKR stock has been trending somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bruker earned a news sentiment score of 0.08 on Accern's scale. They also gave media coverage about the medical research company an impact score of 47.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Bruker's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.37%), Russell Investments Group Ltd. (0.95%), Victory Capital Management Inc. (0.88%), Boston Partners (0.83%), Millennium Management LLC (0.71%) and Dimensional Fund Advisors LP (0.61%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch, Richard A Packer and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sensato Investors LLC, Victory Capital Management Inc., New York State Common Retirement Fund, Massachusetts Financial Services Co. MA, Hsbc Holdings PLC, Citadel Advisors LLC and Teacher Retirement System of Texas. View Insider Buying and Selling for Bruker.

BRKR stock was bought by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Allianz Asset Management GmbH, Point72 Asset Management L.P., Old Mutual Global Investors UK Ltd., Carillon Tower Advisers Inc., Great Lakes Advisors LLC, BlackRock Inc. and GSA Capital Partners LLP. Company insiders that have bought Bruker stock in the last two years include Frank H Laukien and Richard A Packer. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $31.78.

Bruker has a market capitalization of $5.03 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]